Last reviewed · How we verify
NCT05137093
Scratching Validation Study
trial testing Actigraphy Device in Atopic Dermatitis in 27 participants. Completed in 1 February 2023.
1 February 2023
Quick facts
| Lead sponsor | Philips Clinical & Medical Affairs Global |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 27 |
| Start date | 10 December 2021 |
| Primary completion | 1 February 2023 |
| Estimated completion | 1 February 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Actigraphy Device
Conditions studied
- Atopic Dermatitis — all drugs for Atopic Dermatitis →
Sponsor
Philips Clinical & Medical Affairs Global — full company profile →
Who can join
Adults 18 to 75, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Single center, analyst-blinded, study comparing the scratching events identified via an actigraphy scoring algorithm versus manual scoring of an overnight video recording, undertaken in a sample of 40 adult patients with atopic dermatitis and controls.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05137093
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atopic Dermatitis
Currently open trials in the same condition.
- NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
- NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
- NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
- NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
- NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting
Other Philips Clinical & Medical Affairs Global trials
Trials by the same sponsor.
- NCT07521735 — NEXT GEN - PHILIPS OPTIMUS · recruiting
- NCT07368036 — MR 7700 Multinuclear Application Clinical Trial · NA · not yet recruiting
- NCT07449715 — Respiration From Pleth Validation · recruiting
- NCT07317479 — Clinical Study for P-MAR · not yet recruiting
- NCT07317427 — Precise Image for Interventional CT · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05137093 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Philips Clinical & Medical Affairs Global
- Last refreshed: 9 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05137093.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing